Cited by 231Liver Diseases and ImmunityDrug Transport and Resistance MechanismsPediatric Hepatobiliary Diseases and Treatments

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

COMPARISON OF RIFAMPICIN WITH PHENOBARBITONE FOR TREATMENT OF PRURITUS IN BILIARY CIRRHOSIS

Bachs, Laura, Elena, Montserrat, Parés, Albert, Piera, Carlos, Rodés, Joan·1989·The Lancet

DOI 10.1016/s0140-6736(89)91608-5

Open this paper in CoChat — free account

Abstract

The anti-pruritic effects of rifampicin (10 mg/kg) and phenobarbitone (3 mg/kg) were assessed in 22 patients with primary biliary cirrhosis in a crossover randomised clinical trial. Each agent was given for 14 days, with a 30-day washout period between treatments. 21 patients completed the course of rifampicin and 18 that of phenobarbitone; rifampicin was withdrawn from 1 patient when anaemia and renal failure developed, whereas 3 patients stopped taking phenobarbitone because of a rash and the 4th merely refused the drug. Rifampicin had a greater anti-pruritic effect than phenobarbitone. The symptom improved in 19 patients taking rifampicin and in 8 taking phenobarbitone, the degree of improvement being greater with rifampicin than with phenobarbitone. Pruritus disappeared in 9 patients receiving rifampicin, and three of them were free of itch when switching over to phenobarbitone. Both drugs were equally effective in inducing hepatic microsomal function but rifampicin has the additional effect of reducing cholestasis. Its anti-pruritic effect should be tested in long-term clinical trials.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(89)91608-5

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Statistical Methods
Snedecor, G. W., Cochran, W. G., & STOUT, B. B. (1939) · Soil Science · doi:10.1097/00010694-193902000-00006 · Cited by 19,423
Statistical methods in medical research
Menduke, H. (1972) · Journal of the Franklin Institute · doi:10.1016/0016-0032(72)90050-6 · Cited by 1,271
IS URSODEOXYCHOLIC ACID AN EFFECTIVE TREATMENT FOR PRIMARY BILIARY CIRRHOSIS?
Poupon, R. Y., Poupon, R., Calmus, Y., Chrétien, Y., Ballet, F., & Darnis, F. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91610-2 · Cited by 534
The presentation and diagnosis of 100 patients with primary biliary cirrhosis
Sherlock, S., & Scheuer, P. J. (1973) · New England Journal of Medicine · doi:10.1056/nejm197309272891306 · Cited by 504
Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients
Christensen, E., Crowe, J., Doniach, D., Pópper, H., Ranek, L., Rodés, J., Tygstrup, N., & Williams, R. L. (1980) · Gastroenterology · doi:10.1016/0016-5085(80)90571-5 · Cited by 271
Self-citation
Treatment of pruritus of primary biliary cirrhosis with rifampin
Podesta, A., Lopez, P., Terg, R., Villamil, F., Flores, D., Mastai, R., Udaondo, C. B., & Companc, J. P. (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01300759 · Cited by 267
Treatment of pruritus in primary biliary cirrhosis with rifampin
Ghent, C. N., & Carruthers, S. G. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90442-8 · Cited by 257
Mitochondrial Antibodies in Primary Biliary Cirrhosis: Species and Nonspecies Specific Determinants of M2 Antigen
Lindenborn-Fotinos, J., Baum, H., & Berg, P. A. (1985) · Hepatology · doi:10.1002/hep.1840050510 · Cited by 161
Relief of the Pruritus of Jaundice with a Bile-Acid Sequestering Resin
Carey, J. B. (1961) · JAMA · doi:10.1001/jama.1961.03040180034008 · Cited by 134
Phenobarbital Effects in Cholestatic Liver Disease
BLOOMER, J. R., & BOYER, J. L. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-82-3-310 · Cited by 120

Show all 23 references

Research works printed but not linked: 2

Pérez-Ayuso, 1980, Effect of phenobarbital treatment on pruritus and hepatic excretory function in primary biliary cirrhosis, Gastroenterology, 79, 1119
Quintero, 1986, Utilidad del recambio plasmático intermitente en la cirrosis biliar primaria, Gastroenterol Hepatol, 9, 329

Sorted by citations

EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity
Staudinger, J. L., Goodwin, B. J., Jones, S. A., Hawkins‐Brown, D., MacKenzie, K. I., Latour, A. M., Liu, Y., Klaassen, C. D., Brown, K. K., Reinhard, J. F., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051551698 · Cited by 1,378
Primary Biliary Cirrhosis
Schwab, M. (2011) · Springer eBooks · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,241
Primary biliary cirrhosis # †
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Bile salt transporters: molecular characterization, function, and regulation
Trauner, M., & Boyer, J. L. (2003) · Physiological Reviews · doi:10.1152/physrev.00027.2002 · Cited by 999
Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases
Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
The Nuclear Pregnane X Receptor: A Key Regulator of Xenobiotic Metabolism
Kliewer, S. A., Goodwin, B. J., & Willson, T. M. (2002) · Endocrine Reviews · doi:10.1210/er.2001-0038 · Cited by 931
Intrahepatic cholestasis of pregnancy
Geenes, V. L., & Williamson, C. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.2049 · Cited by 702
New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond
Beuers, U., Trauner, M., Jansen, P., & Poupon, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.023 · Cited by 537
Itch: scratching more than the surface
Twycross, R. (2003) · QJM · doi:10.1093/qjmed/hcg002 · Cited by 412
Bile acid transporters and regulatory nuclear receptors in the liver and beyond
Halilbasic, E., Claudel, T., & Trauner, M. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.08.002 · Cited by 415
The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines
Hirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315259 · Cited by 362
Regulation ofCYP3AGene Transcription by the Pregnane X Receptor
Goodwin, B. J., Redinbo, M. R., & Kliewer, S. A. (2002) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.111901.111051 · Cited by 328
Complementary Stimulation of Hepatobiliary Transport and Detoxification Systems by Rifampicin and Ursodeoxycholic Acid in Humans
Marschall, H., Wagner, M., Zollner, G., Fickert, P., Diczfalusy, U., Gumhold, J., Silbert, D., Fuchsbichler, A., Benthin, L., Grundström, R., et al. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.009 · Cited by 321
Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration
Geier, A., Wagner, M., Dietrich, C. G., & Trauner, M. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.04.014 · Cited by 314
Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR)
Sonoda, J., Xie, W., Rosenfeld, J. M., Barwick, J. L., Guzelian, P. S., & Evans, R. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.212494599 · Cited by 281
Treatment of pruritus of primary biliary cirrhosis with rifampin
Podesta, A., Lopez, P., Terg, R., Villamil, F., Flores, D., Mastai, R., Udaondo, C. B., & Companc, J. P. (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01300759 · Cited by 267
Effects of long-term rifampicin administration in primary biliary cirrhosis
Bachs, L., Parés, A., Elena, M., Piera, C., & Rodés, J. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90335-v · Cited by 235
Self-citation
Pharmacology of bile acid receptors: Evolution of bile acids from simple detergents to complex signaling molecules
Copple, B. L., & Li, T. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.12.007 · Cited by 238
Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor
Kliewer, S. A., & Willson, T. M. (2002) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30141-3 · Cited by 232
Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7α-hydroxylase gene transcription
Li, T., & Chiang, J. Y. L. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00258.2004 · Cited by 212
Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis
Prince, M. I., Burt, A. D., & Jones, D. E. J. (2002) · Gut · doi:10.1136/gut.50.3.436 · Cited by 202
The Pruritus of Cholestasis
Jones, A. E., & Bergasa, N. V. (1999) · Hepatology · doi:10.1002/hep.510290450 · Cited by 202
Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study
Terg, R., Coronel, E., Sordá, J., Muñoz, A. E., & Findor, J. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00318-5 · Cited by 199
The efficacy and safety of bile acid binding agents, opioid antagonists or rifampin in the treatment of cholestasis-associated pruritus
Tandon, P., Rowe, B. H., Vandermeer, B., & Bain, V. G. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01200.x · Cited by 176
Enterohepatic transport of bile salts and genetics of cholestasis
Pauli‐Magnus, C., Stieger, B., Meier, Y., Kullak-Ublick, G. A., & Meier, P. J. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.03.017 · Cited by 175
Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials
Khurana, S., & Singh, P. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01326.x · Cited by 162
Molecular Regulation of Hepatobiliary Transport Systems
Trauner, M., Wagner, M., Fickert, P., & Zollner, G. (2005) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000155551.37266.26 · Cited by 163
Nuclear receptors as therapeutic targets in cholestatic liver diseases
Zollner, G., & Trauner, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00030.x · Cited by 146
Natural history of pruritus in primary biliary cirrhosis
Talwalkar, J. A., Souto, E., Jorgensen, R. A., & Lindor, K. D. (2003) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(03)00134-4 · Cited by 141
Evolution and Function of the NR1I Nuclear Hormone Receptor Subfamily (VDR, PXR, and CAR) with Respect to Metabolism of Xenobiotics and Endogenous Compounds
Reschly, E. J., & Krasowski, M. D. (2006) · Current Drug Metabolism · doi:10.2174/138920006776873526 · Cited by 142
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis
You, H., Ma, X., Efe, C., Wang, G., Jeong, S.-H., Abe, K., Duan, W., Chen, S., Kong, Y., Zhang, D., et al. (2022) · Hepatology International · doi:10.1007/s12072-021-10276-6 · Cited by 133
Interventions for tuberculosis control and elimination.
Rieder, H. L., & Disease, L. (2002) · Cited by 129
Pruritus in cholestatic and other liver diseases
Mela, M. G., Mancuso, A., & Burroughs, A. K. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01458.x · Cited by 129
Pathogenesis and Treatment of Pruritus in Cholestasis
Kremer, A. E., Beuers, U. H., Elferink, R. P. J. O., & Pusl, T. (2008) · Drugs · doi:10.2165/00003495-200868150-00006 · Cited by 128
RIFAMPICIN INDUCTION OF CYP3A4 REQUIRES PREGNANE X RECEPTOR CROSS TALK WITH HEPATOCYTE NUCLEAR FACTOR 4α AND COACTIVATORS, AND SUPPRESSION OF SMALL HETERODIMER PARTNER GENE EXPRESSION
Li, T., & Chiang, J. Y. L. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007575 · Cited by 118
Treatment of resistant pruritus from cholestasis with albumin dialysis: Combined analysis of patients from three centers
Parés, A. R., Herrera, M., Avilés, J., Sanz, M., & Mas, A. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.02.031 · Cited by 116
Self-citation
Nuclear Receptors as New Perspective for the Management of Liver Diseases
Trauner, M., & Halilbasic, E. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.044 · Cited by 115
Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis
Pares, A., Cisneros, L., Salmeron, J. M., Caballeria, L., Mas, A., Torras, A., & Rodes, J. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.30204.x · Cited by 112
Self-citation
The pruritus of cholestasis
Bergasa, N. V. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.09.004 · Cited by 112
Pathophysiology and current management of pruritus in liver disease
Kremer, A. E., Elferink, R. P. J. O., & Beuers, U. H. (2011) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2010.10.007 · Cited by 107
Use of Rifampin for Severe Pruritus in Children with Chronic Cholestasis
Yerushalmi, B., Sokol, R. J., Narkewicz, M. R., Smith, D. J., & Karrer, F. M. (1999) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/00005176-199910000-00013 · Cited by 103
Diagnostik und Therapie des hepatozellulären Karzinoms
Greten, T. F., Malek, N. P., Schmidt, S., Arends, J., Bartenstein, P., Bechstein, W. O., Bernatik, T., Bitzer, M., Chavan, A., Dollinger, M. M., et al. (2013) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0033-1355841 · Cited by 101
Parenteral Nutrition‐Associated Liver Complications in Children
Btaiche, I. F., & Khalidi, N. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.3.188.33553 · Cited by 101
Current Concepts in Primary Sclerosing Cholangitis
Wiesner, R. H. (1994) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)61822-9 · Cited by 101
Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases
Halilbasic, E., Baghdasaryan, A., & Trauner, M. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.12.001 · Cited by 100
Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy
Geenes, V., Chambers, J., Khurana, R., Shemer, E. W., Sia, W., Mandair, D., Elias, E., Marschall, H.-U., Hague, W., & Williamson, C. (2015) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2015.03.020 · Cited by 98
Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis
Bellmann, R., Graziadei, I. W., Feistritzer, C., Schwaighofer, H., Stellaard, F., Sturm, E., Wiedermann, C. J., & Joannidis, M. (2004) · Liver Transplantation · doi:10.1002/lt.20001 · Cited by 95
Pregnane X receptor and natural products: beyond drug–drug interactions
Staudinger, J. L., Ding, X., & Lichti-Kaiser, K. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.847 · Cited by 92
British Association of Dermatologists’ guidelines for the investigation and management of generalized pruritus in adults without an underlying dermatosis, 2018
Millington, G. W. M., Collins, A., Lovell, C. R., Leslie, T. A., Yong, A. S. W., Morgan, J. D., Ajithkumar, T., Andrews, M., Rushbook, S. M., Coelho, R. R., et al. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16117 · Cited by 91
Unexpected Clinical Remission of Cholestasis After Rifampicin Therapy in Patients With Normal or Slightly Increased Levels of Γ-Glutamyl Transpeptidase
Cançado, E. L. R., Leitão, R. M. C., Carrilho, F. J., & Laudanna, A. A. (1998) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1998.00472.x · Cited by 89
Effect of oral naltrexone on pruritus in cholestatic patients
Mansour-Ghanaei, F. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i7.1125 · Cited by 89
Pharmacological interventions for pruritus in adult palliative care patients
Siemens, W., Xander, C. J., Meerpohl, J. J., Buroh, S., Antes, G., Schwarzer, G., & Becker, G. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008320.pub3 · Cited by 88
Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity
Zollner, G., Wagner, M., & Trauner, M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.03.005 · Cited by 91
Regulation of Sulfotransferase Enzymes by Prototypical Microsomal Enzyme Inducers in Mice
Alnouti, Y., & Klaassen, C. D. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.129650 · Cited by 87
Pruritus and fatigue in primary biliary cirrhosis
Bergasa, N. V., Mehlman, J. K., & Jones, E. A. (2000) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2000.0109 · Cited by 83
New perspectives for the treatment of cholestasis: Lessons from basic science applied clinically
Boyer, J. L. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.12.001 · Cited by 84
Pathogenesis and Management of Pruritus in PBC and PSC
Kremer, A. E., Namer, B., Bolier, R., Fischer, M. J. M., Elferink, R. P. J. O., & Beuers, U. H. (2015) · Digestive Diseases · doi:10.1159/000440829 · Cited by 84
Advances in Pathogenesis and Management of Pruritus in Cholestasis
Kremer, A. E., Bolier, R., van Dijk, R., Elferink, R. P. J. O., & Beuers, U. H. (2014) · Digestive Diseases · doi:10.1159/000360518 · Cited by 81
Mechanism of Hydrophobic Bile Acid-Induced Hepatocyte Injury and Drug Discovery
Wei, S., Ma, X., & Zhao, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01084 · Cited by 80
The PXR is a drug target for chronic inflammatory liver disease
Wallace, K., Cowie, D. E., Konstantinou, D. K., Hill, S. J., Tjelle, T. E., Axon, A., Koruth, M., White, S. A., Carlsen, H., Mann, D. A., et al. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.04.012 · Cited by 78
Interplay between cholesterol and drug metabolism
Režen, T., Rozman, D., Pascussi, J., & Monostory, K. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2010.05.014 · Cited by 77
Pain as a complication of use of opiate antagonists for symptom control in cholestasis
Mcrae, C. A., Prince, M. I., Hudson, M., Day, C. P., James, O. F. W., & Jones, D. E. J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00879-5 · Cited by 73
The Role of Canalicular ABC Transporters in Cholestasis
Cuperus, F. J. C., Claudel, T., Gautherot, J., Halilbasic, E., & Trauner, M. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.056358 · Cited by 76
Nuclear Receptor Ligands: Rational and Effective Therapy for Chronic Cholestatic Liver Disease?
Boyer, J. L. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.06.053 · Cited by 73
Evolving Concepts of the Pathogenesis and Treatment of the Pruritus of Cholestasis
Jones, E. A., & Bergasa, N. V. (2000) · Canadian Journal of Gastroenterology · doi:10.1155/2000/747495 · Cited by 70
Pruritus in Chronic Cholestatic Liver Disease
Bunchorntavakul, C., & Reddy, K. R. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.03.010 · Cited by 71
Regulation of Transporters by Nuclear Hormone Receptors: Implications during Inflammation
Teng, S., & Piquette‐Miller, M. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700102q · Cited by 74
Pruritus in systemic disease: mechanisms and management
Etter, L., & Myers, S. A. (2002) · Dermatologic Clinics · doi:10.1016/s0733-8635(02)00011-6 · Cited by 67
Hepatic drug transporters and nuclear receptors: Regulation by therapeutic agents
Mottino, A. D., & Catania, V. A. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.7068 · Cited by 67
Pruritus in Primary Biliary Cirrhosis: Pathogenesis and Therapy
Bergasa, N. V. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.013 · Cited by 57
Liver transplantation for primary biliary cirrhosis
MacQuillan, G. C., & Neuberger, J. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00099-0 · Cited by 57
Clinical application of transcriptional activators of bile salt transporters
Baghdasaryan, A., Chiba, P., & Trauner, M. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.12.001 · Cited by 57
Pathogenesis and Treatment of Pruritus
Greaves, M. W. (2010) · Current Allergy and Asthma Reports · doi:10.1007/s11882-010-0117-z · Cited by 54
Treatment of Pruritus Secondary to Liver Disease
Düll, M. M., & Kremer, A. E. (2019) · Current Gastroenterology Reports · doi:10.1007/s11894-019-0713-6 · Cited by 53
Cholestatic pruritus: Emerging mechanisms and therapeutics
Patel, S. P., Vasavda, C., Ho, B. K., Meixiong, J., Dong, X., & Kwatra, S. G. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.04.035 · Cited by 56
Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo‐controlled, cross‐over trial
Prince, M. I., Mitchison, H. C., Ashley, D., Burke, D., Edwards, N., Bramble, M. G., James, O., & Jones, D. E. J. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01398.x · Cited by 52
Effect of rifampicin in the treatment of pruritus in hepatic cholestasis.
Gregorio, G. V., Ball, C., Mowat, A. P., & Mieli‐Vergani, G. (1993) · Archives of Disease in Childhood · doi:10.1136/adc.69.1.141 · Cited by 54
Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study
McCormick, P. A., SCOTT, F. R., Epstein, O., Burroughs, A. K., Scheuer, P. J., & McIntyre, N. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(94)80092-8 · Cited by 51
Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis
Silveira, M. G., & Lindor, K. D. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.873404 · Cited by 50
Functional evolution of the pregnane X receptor
Iyer, M., Reschly, E. J., & Krasowski, M. D. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.3.381 · Cited by 48
Pruritus and fatigue in primary biliary cirrhosis
Bergasa, N. V. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00105-3 · Cited by 48
Clinical features and management of primary biliary cirrhosis
Crosignani, A., Battezzati, P. M., Invernizzi, P., Selmi, C. F., Prina, E., & Podda, M. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3313 · Cited by 46
Transcriptional regulation of hepatobiliary transport systems in health and disease: Implications for a rationale approach to the treatment of intrahepatic cholestasis
Wagner, M., & Trauner, M. (2005) · Annals of Hepatology · doi:10.1016/s1665-2681(19)32071-x · Cited by 47
Pruritis associated with cholestasis
Khandelwal, M., & Malet, P. F. (1994) · Digestive Diseases and Sciences · doi:10.1007/bf02090052 · Cited by 46
Management of Pruritus in Primary Biliary Cholangitis: A Narrative Review
Trivedi, H. D., Lizaola‐Mayo, B., Tapper, E. B., & Bonder, A. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.01.037 · Cited by 46
Advances in primary sclerosing cholongitis
Lindor, K. D., Wiesner, R. H., MacCarty, R. L., Ludwig, J., & LaRusso, N. F. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90101-i · Cited by 45
Nuclear Receptors CAR and PXR; therapeutic targets for cholestatic liver disease
Kakizaki, S. (2011) · Frontiers in bioscience · doi:10.2741/3893 · Cited by 44
Symptoms of PBC – Pathophysiology and management
Khanna, A., Leighton, J., Wong, L. L., & Jones, D. E. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.06.007 · Cited by 44
Extrahepatic manifestations of cholestasis
Glasová, H., & Beuers, U. H. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2002.02717.x · Cited by 43
Rifampicin as an Oral Angiogenesis Inhibitor Targeting Hepatic Cancers
Shichiri, M., Fukai, N., Kono, Y., & Tanaka, Y. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3417 · Cited by 41
Evaluation and Management of Pruritus in Primary Biliary Cholangitis
Düll, M. M., & Kremer, A. E. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.009 · Cited by 41
Liver transplantation for primary biliary cirrhosis
Neuberger, J. (2003) · Autoimmunity Reviews · doi:10.1016/s1568-9972(02)00103-9 · Cited by 40
Medical and Nutritional Management of Cholestasis in Infants and Children
Feranchak, A. P., & Sokol, R. J. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511547409.012 · Cited by 40
Pharmacological interventions for pruritus in adult palliative care patients
Xander, C. J., Meerpohl, J. J., Galandi, D., Buroh, S., Schwarzer, G., Antes, G., & Becker, G. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008320.pub2 · Cited by 40
Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross‐disease cohort study
Webb, G. J., Rahman, S. R., Levy, C., & Hirschfield, G. M. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14579 · Cited by 39
Pruritus in advanced internal diseases Pathogenesis and treatment
Krajnik, M. (2001) · The Netherlands Journal of Medicine · doi:10.1016/s0300-2977(00)00084-x · Cited by 39
Pruritus as a symptom of hepatitis C
Fisher, D. A., & Wright, T. L. (1994) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(94)70072-9 · Cited by 39
Newer Approaches to the Management of Pruritus in Cholestatic Liver Disease
Düll, M. M., & Kremer, A. E. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00517-x · Cited by 42
Diagnostic and therapeutic approach to cholestatic liver disease
Perez, M. T., Serrano, P. L., Tomás, E., Gutiérrez, M. L. G., Lledó, J. L., Cacho, G., Santander, C., & Fernández‐Rodríguez, C. (2004) · Revista Española de Enfermedades Digestivas · doi:10.4321/s1130-01082004000100008 · Cited by 38

Authors: Bachs, L., Elena, M., Parés, A., Piera, C., & Rodés, J.
Affiliations: Hospital Clínic de Barcelona (ES)
Universitat de Barcelona (ES)
ORCID: Parés, Albert
Venue: The Lancet
Publisher: Elsevier BV
Published: 1989-03
Volume: 333
Issue: 8638
Pages: 574-576
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(89)91608-5
OpenAlex: W2088682754
Cited by: 231
References: 23
Citations by year: 2026: 3 · 2025: 3 · 2024: 8 · 2023: 8 · 2022: 6 · 2021: 4 · 2020: 4 · 2019: 6 · 2018: 9 · 2017: 6 · 2016: 8 · 2015: 9 · 2014: 10 · 2013: 4 · 2012: 3
FWCI: 3.40
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
Keywords: rifampicin, phenobarbital, pruritus, primary biliary cirrhosis, antipruritic effect, cholestasis, drug-induced liver injury, anemia, renal failure
MeSH terms: Adult, Cholestasis, Clinical Trials as Topic, Drug Administration Schedule, Female, Humans, Liver Cirrhosis, Biliary, Microsomes, Liver, Middle Aged, Phenobarbital, Pruritus, Random Allocation, Rifampin, Severity of Illness Index

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

COMPARISON OF RIFAMPICIN WITH PHENOBARBITONE FOR TREATMENT OF PRURITUS IN BILIARY CIRRHOSIS

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks